HeartFlow, Inc.

HeartFlow, Inc. is a medical technology company and the global leader in AI-driven coronary artery disease (CAD) management. Its software creates detailed 3D models of the heart from standard coronary CT angiography (CCTA) images, allowing clinicians to assess coronary artery disease without invasive procedures. The company is publicly traded on Nasdaq under the ticker HTFL, with headquarters in San Francisco, California and operations across the United States, Europe and Japan.

The company's flagship platform, HeartFlow One, is described as the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway. It comprises three components: Roadmap Analysis, for visualising and quantifying coronary narrowings; FFRCT Analysis, which assesses the effect of blockages on blood flow through personalised 3D simulations and is supported by ACC/AHA guidelines; and Plaque Analysis, for characterising and quantifying coronary atherosclerosis.

HeartFlow One has been used by more than 1,800 leading institutions and applied to over 600,000 patients. The underlying technology is supported by more than 625 peer-reviewed publications, and 99.5% of U.S. lives are covered through Medicare and major commercial insurers.

Engineering work at HeartFlow spans artificial intelligence and machine learning, medical imaging, 3D modelling and simulation, computational fluid dynamics for blood-flow simulation, coronary plaque quantification, and clinical decision-support software for cardiology diagnostics. The company's stated vision is to transform CAD from the leading cause of death into a disease that can be managed for life.